OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.

Taipei, Taiwan – 7 February 2013 – OBI Pharma, Inc. (GreTai Securities Market Code 4174) held its first extraordinary shareholders’ meeting of the year on the morning of 7 February 2013. This was immediately followed by the election of the company’s 4th Board of Directors and Supervisors, amendment of the articles of association, and the first Board of Directors meeting of the year. Dr Michael Chang (one of the original founders of the company) was elected Chairman of the Board.

The 4th OBI Pharma Board of Directors and Supervisors include: (Directors) Mr Tamon Tseng, Mr Lung-Yeh Cho, Dr Michael Chang, Dr Youe-Kong Shue, Dr Howard S. Lee, Dr Jimmy Y.T. Tsai (independent director), Dr Whaijen Soo (independent director); (Supervisors) Ms Emily Wang, Mr Kuo-Tong Chen.

About OBI Pharma
OBI Pharma, Inc. is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to improve health and the quality of life through innovative and cost-effective therapeutics. OBI Pharma’s focus is on the “Unmet Medical Needs” of challenging diseases, such as Cancer & Infectious Diseases. Additional information can be found at

Bob Chang
19F, No.3, Yuan Qu Street, Nangang District,
Taipei City 11503, TAIWAN
+886-2-2655-8799 ext. 144